Mayzent Tablet, Film Coated
Product Images NDC 0078-0979

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Mayzent (NDC 0078-0979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Siponimod Structural Formula (Baf312 01)

Chemical structure of siponimod illustrating its molecular components, including a trifluoromethyl group and cyclohexyl ring, displayed in a two-dimensional diagram with standard chemical bonds and notation.*

FDA Label Image

Figure 1 Time To Confirmed Disability Progression Based On Edss (study 1) (Baf312 02)

A Kaplan-Meier curve graph comparing the percentage of patients with confirmed EDSS progression over 42 months in a study of Mayzent (siponimod) versus placebo. The graph shows lower progression rates in the Mayzent group with hazard ratio (HR) of 0.79 and a relative risk reduction of 21%. Patient numbers at risk are shown at intervals for each group below the x-axis.*

FDA Label Image

Figure 2 Time To Confirmed Disability Progression Based On Edss (study 1), Subgroup Analysis (Baf312 03)

A forest plot chart showing hazard ratios with 95% confidence intervals for MAYZENT (siponimod) compared to placebo across various subgroups, including relapse history, sex, number of Gd-enhancing T1 lesions, baseline age, and EDSS score at baseline. The chart displays subgroup percentages, event counts for MAYZENT and placebo, and hazard ratios indicating treatment effect.*

FDA Label Image

Novartis Logo (Baf312 04)

MAYZENT 2 mg film-coated tablet packaging by Novartis Pharmaceuticals Corporation. The image shows a white, round tablet with an imprint of 'S 2' on one side, indicating the 2 mg strength of siponimod. The tablet is intended for oral administration.*

FDA Label Image

Principal Display Panel Ndc 0078-0986-15 Rx Only Mayzent® (siponimod) Tablets 2 mg 30 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 05)

Packaging label for MAYZENT (siponimod) tablets, 2 mg strength. The label indicates a quantity of 30 film-coated oral tablets. The product is labeled for prescription use only and advises dispensing with an accompanying medication guide. Manufacturer is Novartis Pharmaceuticals Corporation. Storage instructions and dosage details are partially visible on the right side of the label.*

FDA Label Image

Principal Display Panel Ndc 0078-0979-50 Rx Only Mayzent® (siponimod) Tablets 0.25 mg 28 Tablets Dispense With Accompanying Medication Guide. Novartis (Baf312 06)

MAYZENT 0.25 mg film-coated tablets packaging label showing the proprietary name, generic name (siponimod), strength (0.25 mg), and quantity (28 tablets). The label includes storage instructions, dosage and dispensing notes, NDC 0078-0979-50, Rx only status, and the Novartis Pharmaceuticals Corporation logo and contact information.*

FDA Label Image

Baf312 07

MAYZENT (siponimod) tablets 1 mg oral film-coated tablet package label by Novartis Pharmaceuticals Corporation. The package contains 30 tablets and includes instructions to dispense with accompanying Medication Guide. Storage and dosage information, warnings, and distributor details are printed on the label alongside a barcode and NDC 0078-1014-15.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.